January 5, 2022
Daiichi Sankyo filed a new drug application for its EZH1/2 dual inhibitor valemetostat in Japan on December 28 for the treatment of relapsed/refractory adult T-cell leukemia-lymphoma (ATL). The submission is based on data from a Japan PII study targeting this...read more